Theratechnologies Reports on its Annual Meeting of Shareholders May 29, 2025 02:00PM
Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment Dec 18, 2024 01:30PM
Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025 Sep 17, 2024 05:00PM
Theratechnologies Reports on its Annual Meeting of Shareholders May 9, 2024 04:30PM
Theratechnologies (THTX) Issues Update on Preclinical Oncology Research Program Mar 22, 2024 09:37AM


Mar 22, 2024 09:36AM Theratechnologies Announces Update on its Preclinical Oncology Research Program
Mar 21, 2024 07:30AM Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
Sep 18, 2023 04:15PM Theratechnologies to Announce Third Quarter 2023 Financial Results and Provide Business Update
Sep 7, 2023 01:57PM Theratechnologies to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Jul 12, 2022 07:30AM CQDM, the Quebec Breast Cancer Foundation and Theratechnologies fund close to $2 million for research project to validate the anti-metastatic potential of TH1902 at the Université du Québec à Montr
Jul 8, 2022 09:18AM Pre-Open Movers: Upstart Sinks on Warning, iRhythm Gains on CMS Update
Jan 25, 2021 09:00AM Piramal Pharma Solutions Announces Sterile Fill/Finish Program with Theratechnologies Inc. for TH1902 Peptide-drug Conjugate